Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiobesity pharmacotherapy in the management of Type 2 diabetes
Autore:
Scheen, AJ; Lefebvre, PJ;
Indirizzi:
Univ Liege, CHU Sart Tilman, Dept Med, Div Diabet Nutr & Metab Dis, B-4000Liege 1, Belgium Univ Liege Liege Belgium 1 abet Nutr & Metab Dis, B-4000Liege 1, Belgium
Titolo Testata:
DIABETES-METABOLISM RESEARCH AND REVIEWS
fascicolo: 2, volume: 16, anno: 2000,
pagine: 114 - 124
SICI:
1520-7552(200003/04)16:2<114:APITMO>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CARDIOVASCULAR RISK-FACTORS; INSULIN-DEPENDENT DIABETICS; VALVULAR HEART-DISEASE; BLOOD-GLUCOSE CONTROL; REDUCES BODY-WEIGHT; FREE FATTY-ACIDS; OBESE PATIENTS; GLYCEMIC CONTROL; TERM DEXFENFLURAMINE; DRUG-TREATMENT;
Keywords:
anorectic drugs; insulin resistance; obesity; orlistat; sibutramine; TNF-alpha; Type 2 diabetes; weight loss;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
161
Recensione:
Indirizzi per estratti:
Indirizzo: Scheen, AJ CHU Sart Tilman B35, Div Diabet, B-4000 Liege 1, Belgium CHU Sart Tilman B35 Liege Belgium 1 , B-4000 Liege 1, Belgium
Citazione:
A.J. Scheen e P.J. Lefebvre, "Antiobesity pharmacotherapy in the management of Type 2 diabetes", DIABET M R, 16(2), 2000, pp. 114-124

Abstract

Obesity is a well-known risk factor for the development of Type 2 diabetesmellitus. The management of the obese diabetic patient remains a challengefor the clinician but, in any case, weight reduction should be considered as a key objective. In this respect, several antiobesity drugs have demonstrated potential. However, while fenfluramine and dexfenfluramine have been shown to promote weight loss and to directly improve insulin sensitivity, being two mechanisms contributing to better blood glucose control in obese Type 2 diabetic patients, they were recently withdrawn due to safety problems. Sibutramine, a new selective norepinephrine and serotonin reuptake inhibitor, promotes weight loss by decreasing food intake, an effect which leadsto a mild improvement (significant in patients losing greater than or equal to 5% of initial body weight) of blood glucose control in obese diabetic patients. Similarly, orlistat, a selective gastrointestinal lipase inhibitor which increases faecal fat losses, enhances diet-induced weight reductionand improves both blood glucose control and vascular risk profile, especially dyslipidaemia, in obese Type 2 diabetic patients. Further studies are required to better identify good responders to pharmacotherapy and specify the role of antiobesity agents in the overall long-term management of obese subjects with Type 2 diabetes. Other novel pharmacological approaches deserve further consideration, for instance beta-3 agonists aiming to increase energy expenditure, drugs interfering with tumor necrosis factor-alpha (TNF-alpha) or free fatty acid release by the adipose tissue or agents that slowgastric emptying. However, until now, results regarding efficacy and/or safety have been disappointing or preliminary in humans. Copyright (C) 2000 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 19:20:28